Our Statement on COVID-19

At Principia our focus is on the safety of our employees, patients, and partners. We commenced our COVID-19 preparations at the end of January, and we continue to work with our clinical trial sites and third party manufacturers to maintain momentum of our trials and to provide study drug supply to our sites and patients.

However, these are unprecedented times that pose risks to our business amidst this worldwide disruption and we do not yet know the full impact of this pandemic. We are continuing our operations in a more virtual environment, with the safety of our employees, patients, and partners as our top priority. We are steadfast and unwavering in our goal of bringing transformative therapies to patients with serious immune-mediated diseases.

Principia is now a Sanofi company.

As of September 28, 2020, Sanofi and Principia have joined forces to expand and accelerate the potential benefits of therapies for patients with immune-mediated diseases. We will work together to bring these novel therapies to patients faster. Read press release.

Enter Website